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Abstract
               Andersen-Tawil   syndrome  (ATS)   is   a   rare   condition   consisting   of   ventricular 
arrhythmias, periodic paralysis, and dysmorphic features.  In 2001, mutations in KCNJ2, which 
encodes the α subunit of the potassium channel Kir2.1, were identified in patients with ATS.  To 
date, KCNJ2 is the only gene implicated in ATS, accounting for approximately 60% of cases.  
ATS is a unique channelopathy, and represents the first link between cardiac and skeletal muscle 
excitability.  The arrhythmias observed in ATS are distinctive; patients may be asymptomatic, or 
minimally symptomatic despite a high arrhythmia burden with frequent ventricular ectopy and 
bidirectional ventricular tachycardia.   However, patients remain at risk for life-threatening 
arrhythmias, including torsades de pointes and ventricular fibrillation, albeit less commonly than 
observed in other genetic arrhythmia syndromes.  The characteristic heterogeneity at both the 
genotypic and phenotypic levels contribute to the continued difficulties with appropriate 
diagnosis, risk stratification, and effective therapy.   The initial recognition of a syndromic 
association of clinically diverse symptoms, and the subsequent identification of the underlying 
molecular genetic basis of ATS has enhanced both clinical care, and our understanding of the 
critical function of Kir2.1 on skeletal muscle excitability and cardiac action potential.  
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Introduction
              
               Andersen-Tawil   syndrome   describes   a   rare   condition   consisting   of   ventricular 
arrhythmias, potassium-sensitive periodic paralysis, and developmental anomalies.1,2 While two 
cases of familial periodic paralysis associated with ventricular ectopy were first described in 
1963,3 the suggestion of a potential syndromic association was not proposed until 1971, when 
Ellen Andersen and colleagues described the characteristic triad in an 8 year-old dysmorphic boy 
who experienced episodes of muscle weakness and ventricular extrasystoles.4  Nearly a quarter 
of a century later, 10 previously-described cases were reviewed, in addition to 4 new patients in 
3 kindreds, who appeared to inherit the condition predominantly in an autosomal dominant 
pattern.  Noting for the first time the phenotypically heterogenous nature of this disease, this was 
also the first report to ascribe the name of Andersen’s syndrome to this constellation of 
symptoms.1   Subsequently, the syndrome was renamed Andersen-Tawil Syndrome (ATS) in 
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recognition of the contributions of Dr. Rabi Tawil, who developed diagnostic criteria and refined 
understanding of this entity.5                                                                                                              
               Following   its   initial   characterization,   significant   advances   have   improved   our 
understanding of the genetic basis and molecular aspects of ATS.   In the seminal paper by 
Plaster et al,2  linkage analysis in a large kindred revealed a locus corresponding to a genetic 
region of over 40 cM on chromosome 17q23.  With the notion that both the periodic paralyses 
and abnormalities in myocardial cell repolarization were associated with ion channel mutations, 
so-called channelopathies, the 3 ion channel genes within the linked region (KCNJ2, CACNG1, 
and SCN4A) were suitable candidate genes.  SCN4A was known to underlie periodic paralysis 
without heart or developmental problems,6 and the CACNG1 gene product was not detected in 
heart.  Due to the known function and expression pattern of Kir2.1, the protein encoded by 
KCNJ2, it was considered an excellent candidate gene for ATS.  Eight different mutations in 
KCNJ2 were initially identified in ATS patients, and functional characterization of 2 of the 
mutations revealed dominant negative effects on channel function.  These findings demonstrated 
that ATS mutations in KCNJ2, which encodes the Kir2.1 channel α subunit, appear to markedly 
impair its vital role in stabilizing resting membrane potential and mediating the terminal 
repolarization   phase  of   the   action   potential,   resulting  in  a   predisposition  to  ventricular 
arrhythmias through mechanisms discussed below.                                                                    
               We will review the clinical manifestations of Andersen-Tawil syndrome, including 
distinguishing historical, physical examination, and electrophysiologic findings. We will discuss 
the genetic and molecular aspects of ATS, and will address the characteristic heterogeneity at 
both the genotypic and phenotypic levels.  Finally, we will explore various therapies devised to 
address the primary cause of morbidity and mortality in ATS, namely the propensity for life-
threatening ventricular arrhythmias.                                                            
Clinical Manifestations                                                                                                 
            Since the initial report of Andersen-Tawil syndrome, literature has emerged emphasizing 
the inconsistencies in phenotypic expression and disease severity.7  Such variability has been 
described among kindreds, as well as among members of the same families.8  This variability 
has made the diagnosis of ATS difficult.  In fact, half of the new patients described in the initial 
paper   proposing   the   term   “Andersen’s   syndrome”   were   diagnosed   only   after   repeated 
evaluations.1   Unpredictability   is   seen   not   only   in   dysmorphic   characteristics,   but 
electrophysiologic manifestations as well.  Although ATS is inherited in an autosomal dominant 
pattern, given its heterogenous expressivity, a family history of associated characteristics may 
not be elicited.  In fact, there is up to a 20% incidence of non-penetrance in individuals with 
KCNJ2 mutations.  Additionally, up to 40% of patients with ATS do not have KCNJ2 mutations, 
further   confounding   the   ability   to   utilize   genetic   screening   as   a   diagnostic   tool.5  
Dysmorphic features                                                                                                   
               Appreciation of dysmorphic manifestations comprise one of the three fundamental 
elements   in  the   evaluation  of   ATS.   Features   initially   described  included  short  stature, 
hypertelorism (wide-set eyes), low-set ears, palatal defects, mandibular hypoplasia, single 
palmar crease, crytporchidism, and slight bilateral ptosis.4   In a recent series of 36 KCNJ2 
mutation carriers,  78%  had at  least  two  dysmorphic features,  the  most common  being 
clinodactyly (permanent medial or lateral curvature of a finger or toe, seen in 64%) and 
mandibular   hypoplasia   (44%).8   Other   features   described   have   included   scoliosis, 
hyperthyroidism, vaginal atresia, and unilateral dysplastic kidney; structural cardiovascular 
anomalies such as a bicuspid aortic valve with or without associated coarctation, and valvular 
pulmonic stenosis have been reported as well.9  Also noted in one series was that the severity of 
facial dysmorphism  did  not correlate  with the  severity  of  cardiac  or  skeletal muscular 
involvement.10  
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Periodic Paralysis
               Periodic paralysis serves as another key element to the clinical diagnosis of ATS.  
Historically, the age of onset of weakness is highly variable, though typically within the first two 
decades of life.10  These episodes typically will present before any cardiac symptoms, and are 
usually manifested following periods of prolonged physical exertion.  Examination reveals a 
muscular weakness that is proximal in nature, and may be associated with muscle wasting.  
Attacks have been demonstrated in patients with varying serum potassium levels (either hypo-, 
hyper-, or normokalemia), though levels have been found to remain consistent among an 
individual kindred.2  Potassium challenges have been found to at times either induce or even 
successfully treat episodic weakness.1,10  Noted in one kindred was a sex-specific expressivity, 
with periodic paralysis appearing to segregate as an autosomal dominant trait only among 
males.9   Additional findings have included markedly elevated serum creatine kinase levels, 
normal electromyogram, and tubular aggregates or minimal mypoathic changes apparent on 
pathologic examination of skeletal muscle biopsy.1,8 
Cardiac Manifestations
               True to its variability in phenotypic expression, there exists a wide range of 
electrophysiologic manifestations in ATS.  Some patients have QT interval prolongation, while 
others demonstrate normal QT intervals.  Prominent U waves in the anterior precordial leads are 
common in ATS.11  Although U waves can be observed in normal individuals at low heart rates 
or in hypokalemic states, these are described in ATS patients at higher heart rates, suggesting 
that this may represent a manifestation of disease rather than a normal variant.8  Associated 
arrhythmias range from isolated premature ventricular beats to complex ventricular ectopy and 
polymorphic ventricular tachycardias such as bidirectional ventricular tachycardia or less 
commonly torsades de pointes (see Figure 1).2,11,12  Complete right bundle branch block, left 
bundle branch block, bifasicular block, and first-degree atrioventricular block have also been 
described in patients with known KCNJ2 mutations.8,11   Both nonfatal cardiac arrest with 
documented torsades de pointes, and sudden death, thought to be less common relative to its 
long QT syndrome (LQTS) counterparts, have also been reported.13  Sex-specific expressivity of 
the arrhythmia phenotype has been described in 1 family, where 13 of 16 female carriers, but no 
male carriers, demonstrated a history of ventricular arrhythmias.9  While gender differences in 
cardiac repolarization are well described but not completely understood,14 hormonal modulation 
of arrhythmia risk is suggested by our observation that arrhythmias in ATS may be quiescent 
during pregnancy.  
            The association between ATS and a prolonged corrected QT interval has recently been 
called into question. Citing its relationship to other disorders of myocellular repolarization, 
predisposition to ventricular arrhythmias,  and the purported presence of a prolonged QT interval 
in 71% of all KCNJ2 mutation carriers, it had been suggested that ATS be classified as LQT7.8  
A systematic assessment of ATS patient electrocardiograms was recently completed with 
conflicting results.  Specifically, in ATS patients with and without KCNJ2 mutations, median 
corrected QT intervals were minimally longer (20 ms) than controls, remaining within the 
normal range (median, 440 ms); in fact, only 17% of ATS patients in this series had a QTc of 
over 460 ms.   Additionally, it was noted that those patients possessing KCNJ2 mutations 
appeared to have a distinctive electrocardiographic phenotype, consisting of a prolonged 
terminal T wave downslope, a widened T-U wave junction, as well as biphasic and enlarged U 
waves; such findings were not evident in either ATS patients lacking KCNJ2 mutations or in 
healthy controls.  Accordingly, some now recommend that patients with KCNJ2 mutations be 
classified as ATS1, rather than LQT7.11
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Figure 1.  Ambulatory ECG tracings of ventricular arrhythmias in Andersen-Tawil Syndrome.  
The top panel recorded in a newborn boy with the G144S mutation in KCNJ2 shows sinus 
rhythm with premature ventricular beats in a bigeminal pattern.  The middle and bottom panels 
recorded  in  the  boy’s   mother   with  the  same  mutation  show  runs   of   polymorphic  and 
bidirectional ventricular tachycardia.  
            A well-characterized feature of ATS is its propensity for ventricular arrhythmias. In 
addition to isolated premature ventricular beats, ventricular tachycardias (VT) involving a beat-
to-beat variability in axis (polymorphic ventricular tachycardia), such as bidirectional ventricular 
tachycardia and torsades de pointes, have been described.2,12,15   Torsades de pointes  and its 
potential for progression to life-threatening ventricular fibrillation is a well-known complication 
associated with the prolongation of the plateau phase of the action potential seen in congenital 
and acquired long QT syndromes.16,17  Bidirectional ventricular tachycardia is a distinct form of 
polymorphic VT, characteristically associated with intracellular calcium overload and seen in 
catechecholaminergic polymorphic ventricular tachycardia (CPVT) and digitalis toxicity.12,18,19  
A   relationship   to   intracellular   calcium   overload   and   Na+/Ca2+-mediated   triggering   of 
arrhythmic activity has been proposed in ATS.8   Bidirectional VT, though rare, has been 
described extensively in association with ATS.2  Indeed, bidirectional ventricular tachycardia in 
the absence of other causes should prompt a thorough search for other features of ATS in the 
patient and kindred.  In a cohort of 36 carriers of KCNJ2 mutations, a relatively low rate of 
syncope and cardiac arrest was described, despite a high arrhythmia burden.   Ventricular 
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arrhythmias were noted in 88% of patients, with nonsustained VT present in 65% of probands, 
and bidirectional VT seen in 18% of probands.  Only 2 patients experienced nonfatal cardiac 
arrest (1 with documented  torsades de pointes) and there were 4 episodes of syncope.  
Additionally, there were no cases of sudden cardiac death, nor was there a reported family 
history of sudden death among subjects.8   Interestingly, the incidence of symptoms such as 
syncope in this cohort was less than 20%, markedly lower than the 63% and 46% reported in 
LQT1 and LQT2 syndromes respectively.20                                                                         
            As ATS is a rare disorder, there exists no literature currently which correlates particular 
genotypes or clinical features with an assessment of risk for development of life-threatening 
ventricular arrhythmias and sudden death.  While such reports of sudden death are rare in the 
literature, ATS patients remain predisposed to the development of polymorphic ventricular 
tachycardias such as bidirectional  VT  and  torsades  de pointes; with  their  potential for 
deterioration to ventricular fibrillation and hemodynamic collapse.  These patients consequently 
remain at an increased risk for sudden cardiac death relative to the general population.  
Diagnosis
               Given the heterogenous nature of the clinical manifestations of Andersen-Tawil 
syndrome, a definitive diagnosis at times is elusive.  Manifestation of at least two phenotypic 
classes (skeletal, cardiac, or developmental) has been thought to be necessary for diagnosis of 
ATS.8  While some patients may manifest aspects consistent with all three classes of the clinical 
anomalies, others, (including those with known KCNJ2 mutations) may manifest only a single 
phenotypic classification.   In these instances, some authors have suggested diagnosing such 
patients should they have a substantial family history.5   Noting that to date, about 60% of 
Andersen syndrome patients are found to have mutations in Kir2.1, screening for KCNJ2 
mutations also provides an increasingly valuable tool in either confirming or establishing 
diagnosis in a phenotypically heterogenous condition.
Molecular manifestations
Kir2.1
            Mutations in KCNJ2, which encodes the α-subunit of Kir 2.1, an inwardly-rectifying 
potassium channel, have been identified as the genetic defects underlying the clinical phenotype 
of Andersen-Tawil syndrome.2  The Kir2 family of potassium subunits is expressed in both heart 
and   skeletal   muscle,   and   is   the   first   disordered   channel   associated   with   phenotypic 
manifestations within both skeletal and cardiac muscle.21,22  Kir2.1 subunits form a 427 amino 
acid protein, with 2 transmembrane domains and an extracellular pore forming loop containing 
the GYG amino acid sequence responsible for determining channel selectivity for potassium.  
The Kir2.1 channel functions as an inward rectifier, its conductance changing with voltage 
differences across the membrane.  The term inward rectification indicates that while there is an 
inward flow of potassium current at hyperpolarized potentials, the same voltage gradient with 
depolarization produces much less outward potassium flow.  At potentials more negative to – 20 
mV, the Kir channels increasingly permit potassium efflux, providing a current which mediates 
the terminal phase of repolarization.   The current provided by inward rectifiers such as the 
Kir2.1 channel, termed IK1, has consequently been shown to play a role in the determining 
cardiac excitability, and to “set” the resting potential.23,24  
Kir2.1: Molecular pathology
            Four individual Kir2.1 proteins co-assemble to form a functional tetrameric channel.  
While injection of normal Kir2.1 cRNA into oocytes results in potassium currents with strong 
inward rectification, injection of mutant (D71V and R218W) cRNA into oocytes resulted in no 
detectable current.2  These results raise 2 possibilities: the mutant proteins either failed to co-
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assemble, or assemble normally but impair channel function.  The latter was suggested by the 
finding of “dominant negative” suppression of channel function; > 50% reduction in current with 
coexpression of normal and mutant Kir2.1 subunits.   It is proposed that mutant proteins 
assemble with normal proteins into tetrameric channels, but the presence of 1 or more mutants in 
the channel is sufficient to disrupt current flow.  Assuming random expression and co-assembly, 
only 1 out of every 16 channels would consist of 4 normal subunits, and function normally, 
while 15 of 16 would harbor at least 1 mutant protein.  Indeed, coexpression of the D71V mutant 
cRNA with normal cRNA resulted in a current approximately 1/16th  of normal current.  
            While other mutations have been described involving the external pore forming loop of 
Kir2.1,7  mutations in KCNJ2 impairing channel interactions with phosphatidylinositol 4,5-
bisphosphonate (PIP2) are thought to play a significant role as pathogenic mechanism in ATS.25  
PIP2  is a membrane-bound second messenger which activates Kir2.1, among other inward-
rectifiers, and promotes an open-channel position.5  Also, in vitro it was demonstrated that in 
general (and especially with the previously described R218W mutation), these mutations 
resulted in impaired channel- PIP2  interactions, affecting whole-cell current and marked 
decreases in open-channel probability.25  Consequently, impairments in PIP2 –mediated channel 
function would result in an increase in mean closed time, as has been described, resulting in a 
decrease in channel activity and manifestation of disease phenotype.
Effects of impaired IK1
Decelerates  repolarization/prolongs action potential duration/depolarizes, destabilizes resting 
membrane potential
               The effects of reduced IK1  in a theoretical model of rabbit ventricular myocyte 
demonstrated a prolongation of the terminal phase of the action potential.8   Reductions in 
extracellular potassium concentrations along with decreases in IK1 were also associated with 
development of “terminal-phase” early after depolarizations (EADs), leading to spontaneous 
action potentials and providing a possible explanation for the frequent ventricular ectopy seen in 
patients with ATS.  The term “terminal-phase” was used to distinguish the observed phenomena 
from the typical EAD’s seen in LQTS that arise from the plateau or early repolarization phase of 
the action potential.   Interestingly, also noted was the sodium-calcium exchanger-dependent 
development of delayed after depolarizations, much like those seen with digitalis toxicity.  This 
may   underlie   the   risk   for   bidirectional   VT   that   is   often   observed   in   ATS.  
            Using adenoviral gene transfer techniques, Miake and colleagues were able to further 
delineate the in vivo role of IK1 in cardiac repolarization, studying isolated ventricular myocytes 
from adult guinea pig with both augmented and diminished IK1  expression.26   “Dominant 
negative” reduction in IK1 was achieved by over expression of mutant Kir2.1with the GYG 
potassium selectivity motif replaced with AAA.  This resulted in prolongation of action potential 
duration (APD), deceleration of phase 3 repolarization, and depolarization of the resting 
membrane potential (RMP).  Conversely, over expression of human Kir2.1 with a consequent 
increase  in  IK1  led  to  significant   APD  shortening  with  hyperpolarization  of   RMP  and 
acceleration of phase 3 repolarization. 
               Clinical application of the recent understanding of the role of Kir2.1 and its 
corresponding current, IK1, continues to evolve.   Patients  with ATS and KCNJ2 mutations 
demonstrate a distinct change in U wave morphology, an electrocardiographic characteristic 
associated   with   frequent   premature   ventricular   beats   and   nonsustained   VT,   potentially 
demonstrating   an   increased   vulnerability   to   ventricular   arrhythmia.11   Mutation-induced 
reductions in IK1 have been proposed to lead to a prominent U wave morphology and ventricular 
ectopy through an increase in transmural dispersion of repolarization, leading to action potential 
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duration changes that vary in degree from one region of myocardium to another, and potentially 
serving as the substrate for reentrant arrhythmias.  Interestingly, the gain-of-function mutations 
in KCNJ2 and resulting increases in IK1 have also recently been correlated with disease.  The 
resulting decreases in action potential durations leads to accelerated atrial and ventricular 
repolarization characteristic of the short QT syndrome.   In the form of short QT syndrome 
(SQT3) associated with a KCJN2 mutation, ventricular fibrillation has been observed.27
Molecular Genetics
            ATS occurs sporadically, or is inherited in an autosomal dominant manner.  Mutations in 
KCNJ2 were the first described as responsible for the phenotype of ATS.   Kir2.1 subunits, 
encoded by KCNJ2, combine to form tetrameric channels with additional Kir2.1 subunits,28 or 
with other subunits of the Kir2.x subfamily.29  Mutations in KCNJ2 have been demonstrated to 
impair   Kir2.1   channel   function   usually   through   a   mechanism   of   dominant   negative 
suppression.30   The dominant-negative nature of ATS mutations has been well-described, 
whereby heterogenous expression of wild type Kir2.1 with any number of mutant Kir2.1 
subunits results in a loss of current.2,8,30  Also demonstrated was the ability of mutant Kir2.1 to 
exert dominant-negative suppressive effects upon other members of the Kir2.x subfamily, 
possibly serving as an explanation for the interfamilial phenotypic variations in expressivity.29  
            Between 6-20 % of individuals with identified KCNJ2 mutations appear phenotypically 
normal (non-penetrant).2,5,7-9  Additionally, approximately 30-40% of patients with ATS do not 
harbor KCNJ2 mutations.5,8   In the first demonstration of a relationship between KCJN2 
mutations and ATSs, 3 of 16 families examined had no mutations in the coding regions of 
KCNJ2, with no apparent phenotypic differences in those with KCNJ2 mutations and those 
without.2   Several mechanisms for this genotypic heterogeneity have been proposed, including 
mutations in KCNJ2 regulatory proteins, and mutations in other members of the Kir2.x 
subfamily, as these subunits assemble in heterotetramers to form functional channels.29  
Treatment
               Therapy for ATS is directed toward its phenotypic manifestations which lead to 
significant morbidity, namely associated episodic weakness and most importantly its association 
with life-threatening ventricular tachyarrhythmias.  From initial reports, therapies such as oral 
potassium   supplementation,   sodium   restriction,   spironolactone,   and   acetazolamide   have 
anecdotally been shown to ameliorate symptoms of weakness.1,3,10,31   We have obserevd 
improvement   with   oral   contraceptive   therapy,   with   exacerbation   of   weakness   after 
discontinuation in a female patient with ATS.  Unfortunately, perhaps due to the genotypic and 
phenotypic heterogeneity in disease, in concert with erratic and paradoxical exacerbation of 
symptoms   with   therapy,   no   therapeutic   standards   exist   to   date.  
               While the cardiac sequelae of ATS hold the greatest potential for morbidity and 
mortality, they remain the most problematic in devising effective medical therapeutic options.  
Given the phenotypic heterogeneity that complicates diagnosis, this variability also plays a role 
as a complicating factor in effective risk stratification. The most concerning aspect of ATS, 
paroxysmal ventricular tachycardia leading to syncope or ventricular fibrillation with cardiac 
arrest, is only infrequently inducible with invasive electrophysiologic study.12   Recently, 
radiofrequency catheter ablation targeting premature ventricular beats, which may serve as 
triggers for sustained ventricular arrhythmias, has been performed in other genetic arrhythmia 
syndromes, including LQTS and Brugada syndrome.32,33  This may be an attractive approach in 
ATS due to the frequent ventricular ectopy.  Initial attempts to map ventricular ectopy in patients 
with ATS reveal that the ectopic beats originate from different parts of the left Purkinje network 
(personal communication, P. Sanders, 2005; see Figure 2).  Although to date, catheter ablation 
in ATS has not been reported, in a patient with arrhythmic storms, this approach could be 
considered.  
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Figure 2.  Intracardiac electrograms during spontaneous ventricular ectopy in a patient with 
Andersen-Tawil   syndrome.   Displayed   are   surface   leads   I,   II,   III,   V1,   and   intracardiac 
electrograms recorded from the anterior left ventricle.  The first sinus beat is followed by 2 
successive ventricular ectopic beats, each with a different morphology.  The arrows indicate 
Purkinje potentials preceding the local ventricular electrograms in sinus rhythm and the ectopic 
beats.  The first ectopic beat is from an adjacent Purkinje site – hence the late Purkinje relative to 
the QRS.  (Figure courtesy of Dr. Prashanthan Sanders, Dr. Frederic Sacher, and Dr. Michel 
Haissaguerre, Hôpital Cardiologique du Haut-Lévêque, Bordeaux, France) 
            Successful pharmacologic therapy remains elusive, lacking effectiveness in reducing the 
frequency of ventricular ectopy;12  in fact, even from early reports such therapy has been 
recognized to exacerbate symptoms of weakness.1,3  We have observed similar phenomena: 
improved rhythm control but worsening weakness, or improved muscle strength, but increased 
ventricular ectopy. Reports of antiarrhythmic drug efficacy remain anecdotal, and conflicting. 
While calcium channel blockers are theorized to address the proposed arrhythmogenic substrate 
of intracellular calcium overload, and have been shown to terminate bidirectional VT in ATS,15 
they have also been shown ineffective in reducing ventricular ectopy.12 Similarly, amiodarone 
has been described as a successful therapy for VT in a patient with ATS due to the R218W 
KCNJ2 mutation.31 The authors suggested a possible pharmacogenetic link between the R218W 
mutation   and  treatment   response.   However,   subsequently  amiodarone   was   implicated   in 
inducing  torsades de pointes  in a different ATS patient who also harbored the R218W 
mutation.34 While amiodarone may exacerbate early afterdepolarizations and predispose to TdP 
with its inhibition of IK1 and IKr, its effects in a given patient may not be predictable. Pacing in 
combination with nicorandil was successful in treating ventricular arrhythmias in the   latter 
patient. Pacing, by increasing heart rate and nicorandil, by increasing outward potassium  current 
through IKATP, resulted in attenuation of the prominent U wave,   theoretically reducing 
transmural dispersion of repolarization and  reducing  risk for torsades de pointes.  Beta-blockers 
( including   propranolol,  atenolol,  and   sotalol)    and    sodium   channel   blockers  (including 
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mexiletine,   propafenone,   and   flecainide)   have   been   described   as   ineffective   in   select 
patients.12,31,34  We have used beta-blockers alone, and in combination with calcium channel 
blockers with some success, albeit in a modest number of patients. 
               Aside from preventive measures, an intervention demonstrated to successfully and 
reliably   treat   hemodynamically   unstable   ventricular   tachyarrhythmias   is   the   implantable 
cardioverter-defibrillator (ICD).35  The diagnosis of ATS itself can be considered a class IIb 
indication for ICD placement, citing familial or inherited conditions with a high risk for 
ventricular tachyarrhythmias as a consideration.36  A history of cardiac arrest due to ventricular 
fibrillation or VT would be regarded as a class I indication for ICD placement in ATS, noting 
that there is evidence and/or general agreement that ICD placement is both useful and effective.  
Although sustained VT can also be considered a class I indication for an ICD, many ATS 
patients are asymptomatic during episodes of sustained ventricular tachycardia.12  Until further 
data regarding risk startification becomes available, it seems prudent to reserve ICD therapy for 
ATS patients with a history of cardiac arrest, syncope, or sustained rapid and/or symptomatic 
VT.  Furthermore, ICD programming should be tailored to minimize the risk of multiple shocks 
for VT that may be well tolerated.  Programming no therapy for VT,12 or anti-tachycardia pacing 
rather than shocks for VT have been advocated.37 
Conclusions
               Andersen-Tawil   syndrome is a rare condition with variable expression, caused by 
sporadic mutations or in an autosomal dominant manner.  Mutations in KCNJ2 which encode the 
inwardly rectifying channel Kir2.1 lead to the clinically apparent phenotype of ventricular 
arrhythmias, periodic paralysis, and developmental anomalies.  Marked variation in expression 
confounds ability to diagnose, risk stratify, and effectively treat patients.  ATS differs both on a 
molecular and phenotypic level from the long QT syndromes, and it has been suggested to 
abandon its determination as LQT7.  Effective pharmacologic therapy for associated ventricular 
arrhythmias is lacking, prompting consideration of ICD placement or possibly catheter ablation 
in high-risk patients. 
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